Canaloplasty 2-year clinical results published

Article

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty (circumferential viscodilation and tensioning of the inner wall of Schlemm canal) to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

One hundred and twenty seven patients took part in the clinical study and each patient was enrolled to have the canaloplasty procedure using a flexible microcatheter. At the end of two years the mean IOP of 16.0 mmHg ± 4.2 (SD) and the mean glaucoma medication use of 0.5 ± 0.8. Those eyes with canaloplasty alone were reported as have a mean IOP of 16.3 ± 3.7 mmHg and 0.6 ± 0.8 medications.

As Ophthalmology Times Europe reported as far back as 2006 when we spoke with head researcher, Dr Richard Lewis non-penetrating surgery is becoming more widely accepted in Europe: "I do not feel that uneasiness relating to a lack of knowledge or training is a significant obstacle or barrier to uptake as this unique approach appears far healthier and safer for the eye than trabeculectomy while providing better IOP control." Dr Lewis's results appear to bear out his statement. We will be talking to Dr Lewis in greater depth about the piece in the near future.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.